Thymosin Beta-4
43-Amino Acid Regenerative Peptide · Tissue Repair & Healing
Naturally occurring 43-amino acid peptide crucial for tissue repair, wound healing, and cellular regeneration. Promotes angiogenesis, reduces inflammation, and supports cell migration and differentiation.
Overview
Naturally occurring 43-amino acid peptide crucial for tissue repair, wound healing, and cellular regeneration. Promotes angiogenesis, reduces inflammation, and supports cell migration and differentiation.
Direct systemic delivery provides optimal bioavailability and distribution to target tissues for comprehensive regenerative effects including angiogenesis, cell migration, and differentiation.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Clinical trials show 67% complete healing versus 25% placebo in pressure ulcers.
Enhanced tissue regeneration and reduced healing time in surgical wounds.
Accelerated recovery in muscle, tendon, and ligament injuries.
Phase 2b trials show 43% reduction in infarct size when given within 6 hours.
Improved neurological outcomes and functional recovery in animal models.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- Thymosin peptide
- Chain length
- 43 residues
- Molecular weight
- 4963.44 Da
- Typical dose
- 2-6mg per injection (varies by protocol and severity)
- Frequency
- Daily for acute healing, 2x weekly for maintenance/chronic conditions
- Cycle length
- 2-12 weeks depending on healing needs
- Storage
- Reconstituted: 2-8°C, use within 14 days
Molecular data
- Type
- Thymosin peptide
- Molecular weight
- 4963.44 Da
- Chain length
- 43 residues
Dosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Acute Wound Healing | SubQ | 1.6mg | Daily |
| Cardiac Protection | IV bolus within 6 hours of MI | 42mg | Single dose |
| Chronic Tissue Repair | SubQ | 6mg | Twice weekly |
| Neurological Recovery | IV infusion | 30mg | Three times over 72 hours |
| General Regeneration | SubQ | 2-5mg | Daily or every other day |
| Pressure Ulcer Healing | Direct topical application to wound bed | 1% gel | Once daily |
| Corneal Healing | Topical ophthalmic application | 0.1% drops | 4 times daily |
| Chronic Wound Care | Applied to cleaned wound surface | 0.5% cream | Twice daily |
Interactions
TB-500 is the bioactive fragment of Thymosin β4. Combined use provides full-length peptide benefits plus concentrated bioactive effects.
Complementary healing mechanisms—Tβ4 promotes cell migration and angiogenesis while BPC-157 enhances gastric protection.
No direct interactions reported. Both promote tissue repair through different pathways.
Complementary growth factor effects without direct interaction.
Steroids may reduce effectiveness by inhibiting inflammatory responses necessary for optimal healing.
Tβ4 promotes angiogenesis which may affect bleeding risk. Monitor coagulation parameters.
Theoretical concern about promoting angiogenesis in cancer patients. Avoid during active chemotherapy.
Quality checklist
- ✓Clear, colorless solution when reconstituted
- ✓Proper sterile packaging with intact seals
- ✓Certificate of analysis showing >98% purity
- ✓Appropriate molecular weight confirmed via HPLC/MS
- !Room temperature storage claims—legitimate product requires refrigeration after reconstitution
- ×Cloudy or discolored solution indicating degradation
- ×Crystallization after reconstitution suggesting improper storage
What to expect
Safety
- Mild injection site reactions
- Local inflammation at injection sites
- Severe injection site reactions or persistent inflammation
- Signs of systemic allergic reaction (rash, breathing difficulty)
- Unexpected cardiovascular symptoms during treatment
- Any signs of infection at injection sites
- Active chemotherapy treatment
- Severe systemic allergies to peptides
FAQ
Is Thymosin Beta-4 effective for dry eye or only for wounds?
Thymosin Beta-4 eye drops (0.1% RGN-259) showed Phase 2 efficacy for severe dry eye with significant symptom improvements lasting 28 days post-treatment. Phase 3 trials for neurotrophic keratopathy demonstrated corneal healing and comfort improvements, indicating efficacy beyond general wound healing.
Can Thymosin Beta-4 help with muscle recovery after surgery?
Yes, clinical trials showed Thymosin Beta-4 accelerates post-surgical wound healing by approximately one month in pressure and venous ulcers. This healing acceleration extends to post-surgical tissue repair, making it relevant for accelerating recovery from surgical trauma and improving biomechanical tissue properties.
Why use Thymosin Beta-4 instead of the TB-500 fragment for healing?
Thymosin Beta-4 (full 43 amino acids) provides comprehensive regenerative effects with proven clinical efficacy. TB-500 (7-amino-acid fragment) is more economical and stable. Full-length offers more robust Phase 2 clinical data; fragment offers cost efficiency - both work, choose based on budget and evidence requirements.
Can Thymosin Beta-4 improve cardiac function after a heart attack?
Phase 2b trials showed 43% reduction in heart attack infarct size when Thymosin Beta-4 was administered within 6 hours. It promotes cardiomyocyte migration and survival while stimulating coronary vasculogenesis, indicating potential for cardiac protection, though larger trials are needed for clinical approval.